• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
5N Plus Inc
American Power Group Corp
Atwec Technologies Inc
Bactech Environmental Crp
Blackbaud, Inc. - Common Stock
Computershare Ltd ADR
Entravision Communications Corporation Common Stock
Harvest Gold Crp
Hercules Metals Corp
Marathon Gold Corp
Pathward Financial, Inc. - Common Stock
Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares
Replimune Group, Inc. - Common Stock
Simulations Plus, Inc. - Common Stock
Sprott Inc
Sprott Inc. Common Shares
Tungsten Mng NL
Vicapsys Life Sciences Inc
Voyageur Pharmaceuticals Ltd
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Advaxis, Inc. - Common Stock (OP:ADXS)

0.6036 UNCHANGED
Last Price Updated: 1:47 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.6036
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.6036
Today's Range 0.6036 - 0.6036
52wk Range 0.0333 - 0.7000
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
May 09, 2024
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
March 26, 2024
From Ayala Pharmaceuticals
Via GlobeNewswire

Performance

52-Week Range 13.8% below 52-week high
0.6036
0.0352W Low 0.7052W High

Advaxis, Inc. - Common Stock (ADXS) traded between $0.03 and $0.70 over the past 52 weeks and last traded at $0.60, 13.8% below its 52-week high.

Past 12 Months
N/A
N/A
N/A
N/A
+663.1%
+1712.6%
1W  
1M  
3M  
6M  
YTD +$0.52
1Y +$0.57

ADXS was +1712.6% over the past year, +663.1% year to date.

12 Months vs Market
ADXS
+1712.6%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months ADXS returned +1712.6% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity
YTD
12.4K
1Y
5.4K

More News

Read More
News headline image
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From Immunome, Inc.
Via Business Wire
News headline image
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
November 06, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
October 23, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
October 19, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
August 01, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
July 27, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
July 05, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 05, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023 ↗
May 30, 2023
Via Benzinga
News headline image
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 23, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Inc. (OTC:ADXS) Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors
March 08, 2023
Via News Direct
News headline image
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
March 03, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
February 10, 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ ↗
October 19, 2022
Via Benzinga
News headline image
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
October 19, 2022
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS
March 28, 2022
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
December 22, 2021
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
December 10, 2021
Via Benzinga

Frequently Asked Questions

Is Advaxis, Inc. - Common Stock publicly traded?
Yes, Advaxis, Inc. - Common Stock is publicly traded.
What exchange does Advaxis, Inc. - Common Stock trade on?
Advaxis, Inc. - Common Stock trades on the OTC Traded
What is the ticker symbol for Advaxis, Inc. - Common Stock?
The ticker symbol for Advaxis, Inc. - Common Stock is ADXS on the OTC Traded
What is the current price of Advaxis, Inc. - Common Stock?
The current price of Advaxis, Inc. - Common Stock is 0.6036
When was Advaxis, Inc. - Common Stock last traded?
The last trade of Advaxis, Inc. - Common Stock was at 02/03/26 01:47 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap